We also describe evidence of immunomodulatory intervention of MGF-AuNPs in prostate cancers through observations of enhanced levels of anti-tumor cytokines, such as IL-12 and TNF-α, with concomitant reductions in the levels of pro-tumor cytokines, such as IL-10 and IL-6. Here, IL6 is linked to prostate carcinoma.